Related Experiment Video

Updated: Jul 20, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Targeted therapy for renal cell carcinoma: a new therapeutic paradigm

Philip E Shaheen1, Ronald M Bukowski

  • 1Fellow, Department of Experimental Therapeutics, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Cancer Investigation
|September 20, 2006
PubMed

Insights

Newer therapies are crucial for renal cell carcinoma (RCC), a common kidney cancer with poor treatment response. Targeted agents show promise but require further study for optimal use and combination strategies.

Area of Science:

  • Oncology
  • Nephrology

Background:

  • Renal cell carcinoma (RCC) is the most common kidney tumor, characterized by unpredictable behavior and limited response to traditional systemic therapies.
  • High recurrence rates and the modest efficacy of cytokine therapies (interferon-alpha, interleukin-2) underscore the urgent need for novel treatment strategies.

Purpose of the Study:

  • To review the evolving therapeutic landscape for advanced and metastatic renal cell carcinoma.
  • To highlight the impact of molecularly targeted therapies and biomarkers in revolutionizing RCC treatment.
  • To identify emerging challenges and future directions in the clinical application of targeted antineoplastic agents for RCC.

Main Methods:

  • Review of current literature on targeted therapies for renal cell carcinoma.
  • Analysis of the mechanisms of action for antiangiogenic agents and receptor tyrosine kinase inhibitors.
  • Discussion of clinical investigation trends and emerging therapeutic challenges.

Main Results:

  • Molecularly targeted agents and biomarkers have significantly advanced the treatment paradigm for advanced/metastatic RCC.
  • Antiangiogenic agents and receptor tyrosine kinase inhibitors demonstrate promise but require further investigation into their mechanisms and optimal patient selection.
  • A rapid influx of targeted agents into clinical trials presents new challenges in therapeutic development.

Conclusions:

  • Further research is essential to elucidate the long-term safety and efficacy of targeted agents in renal cell carcinoma.
  • Patient stratification based on biomarkers is critical for maximizing the benefit of targeted therapies.
  • Investigating drug combinations for synergistic or additive effects represents a key future direction in RCC treatment.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...